Chief Scientific Officer
VP, Head of
VP, Enzymology and
VP, Pharmacology and
Chief Scientific Officer
VP, Head of
VP, Enzymology and
VP, Pharmacology and
CEO and President
Chief Medical Officer
Dr. Sachs has 20 years of experience, including over 12 in industry. Prior to assuming the role of Chief Medical Officer at Cogent, she served as Vice President of Clinical Sciences at Cogent, responsible for the clinical development strategy and medical and translational oversight of the Cogent portfolio. Before joining Cogent, Dr. Sachs spent several years at Takeda/Millennium where she led multiple clinical programs in oncology and transplantation, and at Genzyme Corporation, where she was responsible for post-marketing safety surveillance and risk management activities for a variety of oncology products. Dr. Sachs has been a faculty member of the Harvard Medical School since 2007 and is an Assistant in Pediatrics in the Division of Pediatric Hematology/Oncology at the Massachusetts General Hospital. She completed her fellowship in pediatric hematology and oncology at the Dana-Farber Cancer Institute and Children’s Hospital Boston. She received her MD from Washington University in St. Louis and her BS from Duke University. Jessica loves hiking, spending time outdoors, and being with her family.
Chief Scientific Officer
John Robinson is Cogent’s Chief Scientific Officer with over 20 years of small molecule drug discovery experience. He previously served as Vice President of Medicinal Chemistry at Pfizer Boulder Research and Development. John joined Pfizer from Array BioPharma, where he was Executive Director/Head of Chemistry. He started with Array in 2002 and served in a series of scientific and people leadership positions. He received his undergraduate degree in BioChemistry from Indiana University of Pennsylvania and his PhD in Synthetic Organic Chemistry from the University of Delaware. John spends a lot of time coaching high school baseball and youth football in Brighton, CO.
Chief Technology Officer
Chief People Officer
Chief Legal Officer and Corporate Secretary
Chief Financial Officer
Senior Vice President, Medical Affairs & Chief Patient Officer
Managing Member, Fairmount Funds
Peter Harwin is a Managing Member at Fairmount Funds Management LLC, a healthcare investment firm he co-founded in April 2016. Prior to Fairmount, Mr. Harwin was a member of the investment team at Boxer Capital, LLC, part of the Tavistock Group, based in San Diego. Mr. Harwin also serves on the board of directors of Viridian Therapeutics, Inc., Paragon Therapeutics, Inc. and Apogee Therapeutics, LLC. He received his Bachelor of Business Administration from Emory University.
Director of Research, Fairmount Funds
Chris Cain, Ph.D. currently serves as Director of Research at Fairmount Funds Management LLC, a healthcare investment firm based in greater Philadelphia. Prior to joining Fairmount, Dr. Cain served in various positions at the healthcare funds Samsara BioCapital, Apple Tree Partners, and RA Capital Management, where he invested in both public and emerging private biotechnology companies. Before this, Dr. Cain served as a writer and editor at BioCentury Publications. He received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco.
Medical Oncologist and former Pharma-Biotech Executive
Dr. Ferrante is a medical oncologist who has served as a member of our board of directors since February 2018. Dr. Ferrante is the former Chief Medical Officer and Head of Research and Development of Tokai Pharmaceuticals, Inc., a publicly traded biopharmaceutical company where she developed treatments for prostate cancer and other hormonally driven diseases between April 2014 and August 2016. From 2007 to July 2013, Dr. Ferrante held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including Chief Medical Officer and most recently as Oncology Therapeutic Area Head and Cambridge USA Site Head from May 2013 to July 2013. Dr. Ferrante previously held positions of increasing responsibility at Pfizer Global Research and Development and Bristol-Myers Squibb. Dr. Ferrante serves on the board of directors of MacroGenics, Inc. (Nasdaq: MGNX). Dr. Ferrante also served as a director of Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) from 2014 until its acquisition by Lantheus Holdings, Inc. (Nasdaq: LNTH) in 2020 and Baxalta Inc., a previously publicly-traded global biopharmaceutical company from July 2015 until its acquisition by Shire Pharmaceuticals in June 2016. She also served as an advisory board member for Kazia Therapeutics Limited (Nasdaq: KZIA) from 2016 until 2022 and Trillium Therapeutics Inc. (Nasdaq: TRIL) from 2020 until its acquisition by Pfizer in November 2021. She holds an M.D. from Georgetown University and a B.S. in chemistry and biology from Providence College.
Chief Executive Officer, Willow Advisors
Ms. Morris currently serves as Chief Executive Officer of Willow Advisors, a consultancy advising biotech companies on financing, strategy and business development. She brings extensive experience in the pharmaceutical and biotechnology industries from numerous management and board roles. Previously, she spent over a decade leading public biotechnology companies, as Chief Executive Officer of Syndax Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers, and prior, as President and Chief Executive Officer of Affymax, where she led the company through the development of peginesatide (Omontys®). Ms. Morris also held various management and executive positions at Clearview Projects, Coulter Pharmaceutical, Scios Inc., and Johnson & Johnson. She is currently a member of the Board of Directors of Palatin Technologies, Inc. and Viridian Therapeutics, Inc.
Chief Executive Officer, Fore Biotherapeutics
Mr. Ros currently serves as Chief Executive Officer and Director at Fore Biotherapeutics. He has more than 25 years of experience with global pharmaceutical and early-stage biotechnology companies, building and leading teams across sales, marketing, franchise strategy and operations. Prior to joining Fore, he was the Executive Vice President and Chief Strategy and Business Officer of Epizyme, Inc. Prior to Epizyme, Mr. Ros served as Chief Operating Officer and Global Head of the Oncology Business Unit at Sanofi-Genzyme and held leadership positions at ARIAD Pharmaceuticals. Mr. Ros began his career at Bristol-Myers Squibb, where he held positions of increasing responsibility in its Oncology division, contributing to the successful launches of TAXOL, ERBITUX®, SPRYCEL® and IXEMPRA®. Mr. Ros previously served on the Board of Trustees of CancerCARE, a leading national organization dedicated to providing free, professional support services to people affected by cancer.
Mr. Shegog has served as a member of our Board since February 2021. Mr. Shegog has more than 25 years of financial, operations, corporate strategy and compliance expertise in the biotechnology and pharmaceutical industries. He served as Senior Vice President and Chief Financial Officer of Forma Therapeutics, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company, from September 2019 through its acquisition by Nova Nordisk in October 2022. Prior to Forma Therapeutics, Todd most recently served as Chief Financial Officer for Synlogic, where he directed the company’s financial strategy and management as well as facilities and information systems. Before Synlogic, Todd served as Senior Vice President and Chief Financial Officer at Forum Pharmaceuticals, where he was responsible for finance, operations, and information systems during their pursuit of innovative therapies for schizophrenia and Alzheimer’s disease. He also served as the Chief Financial Officer of Millennium Pharmaceuticals, Inc., now Takeda Oncology, where he was responsible for management of the company’s financial resources, corporate planning, financial reporting, and compliance. Todd earned a Bachelor of Science degree in electrical engineering from Lafayette College and an MBA from the Tepper School of Management at Carnegie Mellon University.
CEO and President of Cogent Biosciences
NYU Langone Health
Dr. Kwok-Kin Wong is currently a professor of medicine and director of medical hematology and oncology at the Laura & Isaac Perlmutter Cancer Center at New York Langone Health. He has authored more than 300 peer reviewed publications and is a member of the American Society for Clinical Investigation/the American Association of Physicians (ASCI/AAP).
Dr. Wong’s research, teaching, and clinical activities focus on understanding the genetic alterations driving lung tumor formation and the testing of new targeted and immune lung cancer therapies. His laboratory integrates human cancer genomic studies, the generation of new mouse models of cancers, and novel drug treatment studies. The unique models used in Dr. Wong’s laboratory allow scientists to investigate the efficacy of new targeted therapeutics and immunotherapeutics. Furthermore, these “mouse clinical trials” will help uncover the molecular mechanisms and genetic underpinnings of sensitivity and resistance to targeted therapies and immunotherapy. Insights into these processes gained by Dr. Wong and his team continue to lead us closer to curative treatments for patients with advanced lung cancer.
Anderson Cancer Center
Dr. Verstovsek is the United Energy Resources, Inc., Professor of Medicine and hematologist-oncologist at MD Anderson. Dr. Verstovsek is a global leader in myeloproliferative neoplasms (MPN) and the Founder/Director of the largest MPN Clinical Research Center worldwide. Dr. Verstovsek has achieved international acclaim for his leadership in developing landmark MPN therapeutics. He led more than 60 early/advanced phase clinical trials of novel MPN drugs, including ruxolitinib, the only FDA-approved medication for myelofibrosis (MF) until 2019, and second-line treatment for polycythemia vera. He is leading several pivotal phase 3 trials for promising MPN medications. He has published 24 book chapters, and more than 600 peer-reviewed original articles/reviews in leading medical journals, such as New England Journal of Medicine, Blood, Leukemia, and Lancet. Dr. Verstovsek is lead and senior author of over 80 and 200 articles, respectively (h-index 91).
Dr. Verstovsek received several awards, including the Distinguished Clinical Faculty Mentoring Award (2021), the Waun Ki Hong Faculty Award for Excellence in Team Science (2021), the Otis & Pearl Walters Faculty Achievement Award in Clinical Research (2017), the Seventh Annual Irwin H. Krakoff Award for Excellence in Clinical Research (2013), and the Celgene Young Investigator Award (2010). He was elected member of the American Society for Clinical Investigation in 2015. His contributions have been globally recognized with numerous invitations as expert speaker/educator/Chair at the most significant national/international conferences. He regularly engages at multiple levels with MPN patients’ advocacy groups/societies. He is Co-Founder/Executive Committee Member of the International Working Group for MF Treatment and Research.
Chief Medical Officer, Flatiron Health
Dr. Michael Vasconcelles is currently Chief Medical Officer and Head of the Medical and Scientific Organization at Flatiron Health. Prior to joining Flatiron, Dr. Vasconcelles served as Chief Medical Officer at Unum Therapeutics, a cell and gene therapy company developing autologous engineered T cell products for the treatment of cancer. Prior to Unum, Dr. Vasconcelles spent several years at Takeda/Millennium, where he was Senior Vice President and Head of the Oncology Therapy Area Unit. In his role, he was accountable for strategic and operational oversight of the oncology research and development portfolio globally. He was also a member of the Takeda Research and Development executive management team. Prior to Takeda/Millennium, Dr. Vasconcelles spent 12 years at Genzyme in roles of increasing responsibility, most recently as Group Vice President, and Therapeutic Area Head of Transplant and Oncology. In this capacity, he was the senior R&D executive on the Genzyme Transplant and Oncology Management Team, holding accountability for the transplant and oncology research and development portfolio.
From 1994-2021, Dr. Vasconcelles was a faculty member of the Harvard Medical School and an Associate Physician at the Dana-Farber Cancer Institute and the Brigham & Women’s Hospital. Dr. Vasconcelles serves on the Board of Directors at Molecular Partners, a clinical-stage biotechnology company based in Zurich, Switzerland. He is a member of numerous professional societies, including the American Society of Clinical Oncology and the American Society of Hematology. His board commitments have included the Personalized Medicine Coalition and the eastern New England board of the American Cancer Society. Dr. Vasconcelles has served as a grant reviewer for the United States National Institutes of Health (NIH) and the Cancer Prevention and Research Institute of Texas. He has been the recipient of several research grants from the NIH and has been published in peer-reviewed journals such as the Journal of Clinical Oncology, Journal of Biological Chemistry, Molecular and Cellular Biology, and the
Journal of Immunotherapy.
Massachusetts General Hospital Cancer Center
Dr. Ryan Corcoran is the Director of the Gastrointestinal Cancer Center Program and the Scientific Director of the Termeer Center for Targeted Therapy at the Massachusetts General Hospital Cancer Center. He is an Associate Professor of Medicine at Harvard Medical School. Dr. Corcoran graduated from Princeton University with an AB in Molecular Biology and received an MD and a PhD in Cancer Biology from the Stanford University School of Medicine. He completed his residency training in Internal Medicine at the Massachusetts General Hospital and his fellowship training in Medical Oncology at the Dana-Farber Cancer Institute and the Massachusetts General Hospital Cancer Center.
Dr. Corcoran directs a research laboratory focused on the development of therapeutic strategies that
target the specific mutations driving individual patients’ tumors and understanding molecular
determinants of response or resistance to anti-cancer therapies. Dr. Corcoran’s laboratory is also
studying new ways to utilize liquid biopsy and specific analysis of circulating tumor DNA in the clinic to optimize how we deliver cancer care to individual patients. Through his continued translational work in these areas, Dr. Corcoran strives to integrate both laboratory and clinical research efforts to more rapidly develop new and effective treatments for patients suffering from these lethal cancers.
Laura and Isaac Perlmutter Cancer Center
Dr. Adams is a Professor of Medicine at the NYU Grossman School of Medicine and Director of the Breast Cancer Center at the Laura and Isaac Perlmutter Cancer Center, an NCI-designated Comprehensive Cancer Center in New York, USA. As an internationally recognized expert in breast cancer immunotherapy, she has led groundbreaking research and clinical studies leading to the first chemo-immunotherapy approval for breast cancer. She is a member of the ECOG-ACRIN Breast Cancer Committee, has served on various ASCO committees as well as a member of the NCI Clinical Oncology Study Section and at present co-chairs the NCI Breast Cancer Immuno-Oncology Task Force. Her research has been supported by grants from the American Society of Clinical Oncology, the New York State Department of Health, the Department of Defense, and the National Cancer Institute. She also completed a Master of Science in Clinical Investigation at NYU and chairs the Data and Safety Monitoring Board of the NYU Perlmutter Cancer Center.
Senior Vice President, Regulatory Affairs